Brief: Vicore Pharma Posts Q4 Operating Loss of SEK 63 Million
28/02/2023 07:17
Feb 28 (Reuters) - Vicore Pharma Q4 adjusted free cash flow SEK -100.3 million. * Q4 adjusted EPS SEK -0.83 * Q4 sales SEK 0 * Q4 cash and investments SEK 261.7 million
Recent news on Vicore Pharma Holding AB
See all newsBrief: Vicore Pharma Holding Q3 Net Revenues Amounted To Sek 0.6 Mln
Brief: Vicore Pharma Holding AB Phase 2B Aspire Trial Of Buloxibutid In Ipf Passes Pre-Planned Futility Analysis, On Track For Mid-2027 Topline Results
Brief: Vicore Pharma Q2 Operating Loss At SEK 150.1 Million
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:53 PM
Brief: Vicore Pharma Shares Start Trading In US On July 2